

# **EXHIBIT 55**

1 UNITED STATES DISTRICT COURT  
2 DISTRICT OF MASSACHUSETTS  
3 Civil Action No. 05-12237 WGY  
4

AMGEN, INC.,

) DEPOSITION OF:

) CHRYS KOKINO

Plaintiff

)

)

vs.

) \*\*HIGHLY CONFIDENTIAL\*\*

) \*\*\*RESTRICTED ACCESS\*\*\*

F. HOFFMANN-LA ROCHE LTD., a

)

Swiss Company, ROCHE

)

DIAGNOSTICS GmbH, a German

)

Company, and HOFFMANN-LA

)

ROCHE, INC., A New Jersey

)

Corporation,

)

)

Defendants.

)

12 TRANSCRIPT of the stenographic notes of the  
13 proceedings in the above-entitled matter, as taken by and  
14 before MARGARET M. REIHL, RPR, CRR, CSR, Notary Public of the  
15 State of New Jersey, held at the offices of GIBBONS, One  
16 Gateway Center, Newark, New Jersey, on Thursday, March 15,  
17 2007, commencing at 9:06 a.m.  
18  
19

(This transcript has been designated  
20 as Highly Confidential as per the Amended  
Protective Order in this matter. Please  
21 treat the entire transcript in accordance  
with the Protective Order.)  
22  
23  
24  
25

1 MR. FLEMING: Okay.

2 BY MR. DUBROW:

3 Q. But -- so because you don't have a label -- as  
4 of today you don't have a label, correct?

5 A. Correct.

6 Q. You don't have FDA approval, correct?

7 A. Correct.

8 Q. You haven't determined pricing, correct?

9 A. Correct.

10 Q. You haven't offered Mircera to customers for  
11 sale?

12 A. No.

13 Q. You have not put marketing materials out to  
14 the public regarding Cera, correct?

15 A. Yes, that's correct.

16 Q. And as of today you don't know the amount of  
17 demand that you will be able to generate for Cera if  
18 you do obtain FDA approval, correct?

19 MR. FLEMING: Objection,  
20 mischaracterizes his testimony.

21 THE WITNESS: My hope is that there  
22 would be much demand for this product, based on the  
23 clinical characteristics of the molecule, and the fact  
24 that there would be a therapeutic option for patients,  
25 I would expect there to be a significant demand.